

1 **Title: Impact of long-term COVID on workers: a systematic**  
2 **review protocol**

3 *Short title:* Long-term COVID on workers

4 **Authors:**

5 Camila Bruneli do Prado<sup>1\*</sup>, Master student. ORCID: [https://orcid.org/0000-0002-1762-](https://orcid.org/0000-0002-1762-6064)  
6 [6064](https://orcid.org/0000-0002-1762-6064). E-mail: [prado.camilab@gmail.com](mailto:prado.camilab@gmail.com)

7 Giselly Storch Emerick<sup>1</sup>, Master student. ORCID: [https://orcid.org/0000-0001-7056-](https://orcid.org/0000-0001-7056-0159)  
8 [0159](https://orcid.org/0000-0001-7056-0159). E-mail: [gisaemerick1@gmail.com](mailto:gisaemerick1@gmail.com)

9 Luciana Bicalho Cevolani Pires<sup>2</sup>, Master student. ORCID: [https://orcid.org/0000-0002-](https://orcid.org/0000-0002-2760-9663)  
10 [2760-9663](https://orcid.org/0000-0002-2760-9663). E-mail: [lubicenutricao@gmail.com](mailto:lubicenutricao@gmail.com)

11 Luciane Bresciani Salaroli<sup>1,2</sup>, Ph.D. ORCID: <https://orcid.org/0000-0002-1881-0306>. E-  
12 mail: [lucianebresciani@gmail.com](mailto:lucianebresciani@gmail.com)

13

14

15

15 **Affiliations:**

16

<sup>1</sup> Graduate Program in Collective Health, Health Sciences Center, Federal University of Espírito Santo, Vitória, Espírito Santo, Brazil.

17

18

<sup>2</sup> Graduate Program in Nutrition and Health, Health Sciences Center, Federal University of Espírito Santo, Vitória, Espírito Santo, Brazil.

19

20

21

22

**Corresponding author:** Camila Bruneli do Prado. Master student. Graduate Program in Collective Health, Health Sciences Center, Federal University of Espírito Santo (UFES), Av. Marechal Campos, 1468 – Maruípe, Zip Code: 29.043-900, Vitória, Espírito Santo, Brazil. E-mail: [prado.camilab@gmail.com]. Phone: +55(28)99973-3515. ORCID: <https://orcid.org/0000-0002-1762-6064>

23

24

25

26

27

28

29

29 **Author Contributions**

30

These authors contributed equally to this work.

31

32

33

**Competing interests:** None declared.

34

**Acknowledgments:** None declared.

35

**Funding:** This study protocol has no financial support.

36

37

38

39

40

41

42

43

44

45

## 1 Abstract

2 Introduction: Part of the patients infected by COVID-19 have at least one lasting sequel  
3 of the disease and may be framed in the concept of long Covid. These sequelae can  
4 compromise the quality of life, increase dependence on other people for personal care,  
5 impair the performance of activities of daily living, thus compromising work activities  
6 and harming the health of the worker. This protocol aims to critically synthesize the  
7 scientific evidence on the effects of Covid-19 among workers and its impact on their  
8 health status and professional life.

9 Method: Searches will be performed in MEDLINE via PubMed, EMBASE, Cochrane  
10 Library, Web of Science, Scopus, LILACS and Epistemonikos. Included studies will be  
11 those that report the prevalence of long-term signs and symptoms in workers and/or the  
12 impact on their health status and work performance, which may be associated with Covid-  
13 19 infection. Data extraction will be conducted by 3 reviewers independently. For data  
14 synthesis, a results report will be carried out, based on the main outcome of this study.

15 Discussion: This review will provide evidence to support health surveillance to help  
16 decision makers (i.e. healthcare providers, stakeholders and governments) regarding  
17 long-term Covid.

18  
19

## 20 Introduction

21 On December 31, 2019, the World Health Organization (WHO) was informed of  
22 unknown microbial pneumonia cases associated with Wuhan City, Hubei Province, China  
23 [1]. It was a new strain of coronavirus that had not been identified before in humans that  
24 soon spread rapidly around the world, leading the WHO to declare a public health  
25 emergency of international concern on January 30, 2020 [2] and a pandemic on 11  
26 January 2020. March 2020 [3].

27 This new coronavirus (SARS-CoV-2), responsible for causing the severe acute  
28 respiratory syndrome called COVID-19, [4] which has been the focus of attention for  
29 scientists, authorities, public health agencies, government officials and communities  
30 around the world [5].

31 As of mid-January 2022, there were 278 million confirmed cases worldwide,  
32 including 5.4 deaths, reported to the WHO due to COVID-19 [6]. It should be noted that  
33 the total number of subjects who have already been infected is likely to be higher, due to  
34 insufficient testing in many countries, as well as the difficulty in diagnosing mild cases  
35 of the disease [7].

36 The acute clinical features of COVID-19 involve pulmonary and extrapulmonary  
37 systemic manifestations, causing heterogeneous symptoms such as fever, dyspnea, cough,  
38 myalgia, generalized fatigue, anosmia and dysgeusia in milder cases [8]. Of the infected  
39 population, 30% evolve without symptoms, 55% have mild and moderate symptoms of  
40 the disease, and approximately 15-20% develop more severe manifestations and require  
41 hospitalization [9].

42 Studies show that patients who survive COVID-19, regardless of the clinical form,  
43 in the acute phase of the disease, have had a prolonged stay, both in the ICU and in  
44 hospital wards, which can evolve to a complex association of cognitive, psychological  
45 and motor symptoms, which has been called "Post- COVID-19 Syndrome" [10].

46 The nomenclature to be used for this complex association of post-COVID  
47 symptoms is not yet consolidated and several synonyms have been seen such as "Post-  
48 COVID Syndrome", "Long covid", "Late sequelae of COVID-19" or "post-acute  
49 COVID-19" [11]. Long-term Covid is conceptually defined as persistent symptoms  
50 and/or late complications that people may develop four or more weeks after being infected  
51 with the virus that causes COVID-19 [12].

52 More than 80% of infected patients have at least one lasting sequelae of COVID-19,  
53 which may be framed in the concept of long covid [13], causing a decrease in quality of  
54 life, increased dependence on other people for personal care and impaired performance  
55 of the activities of the daily life [14].

56 In this context, it is noteworthy that the consequences of COVID-19 can  
57 compromise work activities and harm the health of the worker, causing social and  
58 economic impacts, since they need to be away from work for health treatment, generating  
59 a shortage of manpower. for these áreas [15]. The delay in returning to work considerably  
60 increases the chances of losing a job, which can lead to physical and mental problems.  
61 When the absence from work lasts more than 6 months, the chance of readaptation to  
62 work in the same role drops to 50% [16].

63 Work capacity is a dynamic process, in which the worker is able to fulfill the  
64 requirements of his tasks, using his physical and mental abilities according to his health  
65 conditions [17]. Factors such as lifestyle, social characteristics, work requirements,  
66 among others, significantly interfere in this process [16].

67 That said, the SARS-CoV-2 pandemic creates new challenges for occupational  
68 health mainly related to the return to work for those affected by long-term symptoms.

69 Complaints of muscle weakness, memory and concentration difficulties can  
70 develop over time, including after returning to work. When this occurs, there is not always  
71 recognition or association with COVID-19 [18].

72 In view of the above, it is relevant to carry out a synthesis of the scientific evidence  
73 on the effects of COVID -19 among workers, its impact on their health status and  
74 professional life, in order to provide subsidies for the development of follow-up and care  
75 actions with workers' health.

76

77

## 78 **Methods and analysis**

79

### 80 **Research objectives**

81 The objective of this systematic review is to critically synthesize the scientific evidence  
82 on the effects of long-term COVID-19 among workers and its impact on health status and  
83 working life.

84

### 85 **Search strategy**

86 The search strategy will be carried out in order to increase methodological  
87 transparency and improve the reproducibility of the findings, following the PRISMA  
88 checklist. Additionally, using the acronym PECO (Population / Exposure / Comparison /

89 Outcomes) [19], we elaborated the guiding question of this review, to ensure the  
 90 systematic search of the scientific literature: 'What scientific evidence is available on the  
 91 impact of long-term COVID-19 on workers? The protocol was registered in the  
 92 International Prospective Registry of Systematic Reviews (PROSPERO) in November  
 93 2021 (registration ID: CRD42021288120).

94 The search strategy will be carried out through 07 specialized and general  
 95 databases, from the beginning until April 30, 2021: Medical Literature Analysis and  
 96 Retrieval System Online (MEDLINE) via Pubmed, EMBASE (Excerpta Medica  
 97 dataBASE), Cochrane Library, Web of Science, Scopus, Latin American and Caribbean  
 98 Literature in Health Sciences (LILACS) and Epistemonikos.

99 In addition, secondary searches will also be carried out in other sources, such as  
 100 the World Health Organization (WHO) - Global Literature on Coronavirus Disease, ,  
 101 Google Scholar and medRxiv. The reference section of included studies will be manually  
 102 searched for additional relevant studies. There will be no restriction on publication date  
 103 or languages in this systematic review. The search strategy will only understand the key  
 104 terms according to a pre-established PECO acronym. EndNote bibliographic software  
 105 will be used to store, organize and manage all references and ensure a systematic and  
 106 comprehensive search. The selection of studies will be performed by three independent  
 107 researchers (CBP, GSE and LBCP) using Rayyan software.

108 First, we will identify the existence of subject-specific header indexes in each  
 109 database (such as MeSH terms, Emtree terms, and DeCS-Health Science Descriptors) and  
 110 their synonyms (keywords) and additional terms. Search terms will be combined using  
 111 the boolean operators 'AND' and 'OR' [20]. The search strategy combining MeSH terms  
 112 and keywords that will be used in MEDLINE is described in table 1; it will be adapted to  
 113 meet the specific syntax requirements of each database.

114 Possible changes to the protocol will be described in the publication of the final  
 115 report, which should be developed according to the preferred reporting items for  
 116 systematic reviews and meta-analyses [21]. The preliminary pilot search strategy  
 117 combining MeSH terms, synonyms, and keywords to be used in MEDLINE/PubMed is  
 118 detailed in Table 1.  
 119

**Table 1.** Preliminary pilot Search strategy in MEDLINE/PubMed

Databases	Searchs items
MEDLINE/PubMed	#1 (“Occupational Groups” [MeSH Terms]) OR “Employees” [All Fields] OR “Personnel” [All Fields] OR “Workers” [All Fields] OR “Group, Occupational” [All Fields] OR “Groups, Occupational” [All Fields] OR “Occupational Group” [All Fields] OR “Employee” [All Fields] OR “Worker” [All Fields]) #2 (“COVID-19” [MeSH Terms]) OR "COVID 19" [All Fields] OR "SARS- CoV-2 Infection" [All Fields] OR "Infection, SARS-CoV-2" [All Fields] OR "SARS CoV 2 Infection" [All Fields] OR "SARS-CoV-2 Infections" [All Fields] OR "2019 Novel Coronavirus Disease" [All Fields] OR "2019 Novel Coronavirus Infection" [All Fields] OR "2019-nCoV Disease" [All Fields] OR "2019 nCoV Disease" [All Fields] OR "2019-nCoV Diseases" [All Fields] OR "Disease, 2019-nCoV" [All Fields] OR "COVID-19 Virus Infection" [All Fields] OR "COVID 19 Virus Infection" [All Fields] OR "COVID-19 Virus Infections" [All Fields] OOR "Virus Infection, COVID-19" [All Fields] OR "Coronavirus Disease 2019" [All Fields] OR "Disease 2019, Coronavirus" [All Fields] OR "Coronavirus Disease-19" [All Fields] OR "Coronavirus Disease 19" [All Fields] OR "Severe Acute Respiratory Syndrome Coronavirus 2 Infection" [All Fields] OR "SARS Coronavirus 2 Infection" [All Fields] OR "COVID-19 Virus Disease" [All Fields] OR "COVID 19 Virus Disease" [All Fields] OR "Disease, COVID-19 Virus" [All Fields] OR "Virus Disease, COVID-19" [All Fields] OR "2019-nCoV Infection" [All Fields] OR "2019 nCoV Infection" [All Fields] OR "2019-nCoV Infections" [All Fields]

"Infection, 2019-nCoV" [All Fields] OR "COVID19" [All Fields] OR "COVID-19 Pandemic" [All Fields] OR "COVID 19 Pandemic" [All Fields] OR "Pandemic, COVID-19" [All Fields] OR "COVID-19 Pandemics" [All Fields] OR "SARS-CoV-2 variants" [Supplementary Concept]

#3 = #1 AND #2

#4 ("COVID-19/complications" [MESH TERMS]) OR "post-acute COVID-19 syndrome" [Supplementary Concept] OR "long-COVID" [All Fields] OR "long-haul COVID" [All Fields] OR "post-acute sequelae of SARS-CoV-2 infection" [All Fields] OR "chronic COVID syndrome" [All Fields] OR "post-acute COVID19 syndrome" [All Fields] OR "long hauler COVID" [All Fields] OR "long COVID" [All Fields] OR "long haul COVID" [All Fields] OR "post-acute COVID syndrome" [All Fields] OR "persistent COVID-19" [All Fields]

#5 = #3 AND #4

120 Source: The authors, 2021.

121

## 122 Selection of studies

123 The CEEC strategy is detailed in table 2.

124

**Table 2.** Inclusion and exclusion criteria.

PECOS acronym	Inclusion criteria	Exclusion criteria
P - Patient/Population	Worker of both sexes, of any ethnicity.	Non-workers
E - Exposure	Patients with confirmed COVID-19	Other previous pandemics
C - Control or Comparison	Not applicable	-
O - Outcomes	The primary outcomes will be the prevalence of long covid symptoms in workers and/or the impact on their health status and work performance.	-----

125 Source: The authors, 2021.

126

127 With regard to study design, primary research studies will be included, including  
128 observational studies (e.g. prospective cohort studies, retrospective case reviews),  
129 intervention studies (e.g. randomized controlled trials, single-arm studies) and systematic  
130 reviews. Secondary research reports (eg non-systematic review articles, news articles,  
131 commentary articles, opinion articles) will be excluded. With regard to the characteristics  
132 of the population, workers of both sexes and of any ethnicity will be included.

133 The primary outcomes will be the prevalence of long-term signs and symptoms in  
134 workers and/or the impact on their health status and work performance that may be  
135 associated with COVID-19 infection.

136 The screening and selection of studies will be carried out by three reviewers (CBP,  
137 GSE and LBCP) independently. Any disagreement will be arbitrated by a fourth reviewer  
138 (LBS). The Rayyan application, developed by the Qatar Computing Research Institute,  
139 will be used as an auxiliary tool for data management [22].

140

## 141 Screening

142 The literature obtained will be imported into Endnote for title and abstract  
143 screening, after importing the documents retrieved from the initial searches, duplicates  
144 and studies that do not meet the pre-specified inclusion criteria will be excluded and three  
145 reviewers (CBP, GSE and LBCP) will independently screen studies based on their titles

146 and abstracts. If there is a good agreement between the reviewers (at least 80%), each one  
147 will proceed with the complete screening of the article. If there is agreement below 80%,  
148 the articles will be re-evaluated, and differences will be discussed and resolved by  
149 consensus; if a disagreement persists, a fourth reviewer (LBS) will make the final decision  
150 using the Rayyan app.

151 After reading the full text of the other studies, the final studies included will be  
152 determined. The corresponding author of any original study will be contacted when the  
153 full text is not available. The entire study selection process is presented in a PRISMA  
154 flowchart [21].

## 156 **Data extraction**

157 Full-text screening will be performed by the same independent investigators. To  
158 measure agreement between coders during each screening phase, Cohen's kappa will be  
159 performed. Once consensus is reached on the selected studies, a standardized form will  
160 be used for data extraction: The information to be extracted includes four domains: (1)  
161 study identification (article title, journal title, impact factor, authors, study country,  
162 language, funding sources, year of publication, study host institution (hospital, university,  
163 research center, single institution and multicenter study), conflicts of interest and study  
164 sponsorship); (2) methodological characteristics (study design, study objective or  
165 research question or hypothesis, sample characteristics, eg sample size, age, sex,  
166 eligibility criteria, ethnicity and baseline characteristics, groups and controls, methods of  
167 study recruitment and completion rates, comparator group, time period for follow-up,  
168 validated measures, costs and/or fees related to participation, statistical analyzes and  
169 adjustments); (3) main findings and implications for clinical practice; and (4) conclusions.  
170 The same three reviewers will perform the data extraction independently. Discrepancies  
171 between reviewers will be resolved by discussion or, failing agreement, by a fourth  
172 reviewer (LBS).

## 174 **Methodological evaluation**

175 For internal validity and risk of bias for observational studies, the Methodological  
176 Index for Non-Randomized Studies (MINORS) will be used. This MINORS instrument  
177 contains eight items for observational studies: (1) a clearly stated objective; (2) inclusion  
178 of consecutive patients; (3) prospective data collection; (4) outcomes appropriate to the  
179 purpose of the study; (5) unbiased assessment of the study outcome; (6) follow-up period  
180 appropriate to the purpose of the study; (7) loss to follow-up of less than 5%; and (8)  
181 prospective study size calculation. All items in the MINORS tool will be evaluated from  
182 0 to 2, with a score of 0 indicating that the information was not reported, 1 indicating that  
183 the information was reported inappropriately and 2 indicating that the information was  
184 reported properly [23].

185 The same three reviewers (CBP, GSE and LBCP) will independently conduct the  
186 quality assessment. Disagreements will be resolved by a fourth reviewer (LBS). Based  
187 on the assessment of these domains, studies are classified as low, high, or uncertain risk  
188 of bias.

## 190 **Data synthesis**

191 If it is not possible to perform meta-analyses, a formal narrative synthesis will be  
192 performed according to the Synthesis Without Meta-Analysis (SWiM) guidelines, to  
193 obtain data on the prevalence of symptoms of long-term lust in workers and/or the impact  
194 on their health status and work performance.

195 For data synthesis, a results report will be carried out, based on the main outcome  
196 of this study. The grouping of studies for synthesis will be based on long and ambiguous  
197 outcome, study design (observational studies), risk of bias assessments (studies with low  
198 risk of bias), studies that answer the review question. To analyze the quality of the studies,  
199 the MINORS tool will be used.

200 For the critical analysis of the findings, guidelines published by national and  
201 international authorities, such as the World Health Organization, the Ministry of Health  
202 and the State Health Departments will be used.

203 To investigate heterogeneity, the data found will be organized into tables,  
204 specifying the methodological, sociodemographic characteristics (for example, sex, age),  
205 professional category, type of work during the COVID-19 pandemic (remote / face-to-  
206 face), severity of symptoms of long covid, clearly referencing all studies included in the  
207 review. Prevalence ratio, p-value, confidence intervals, hazard ratio, odds ratio and odds  
208 ratio will be described.

209 Heterogeneity will also be tested by the  $I^2$  statistic, which can quantify  
210 heterogeneity ranging from 0% (no heterogeneity) to 100% (differences between effect  
211 sizes can be completely explained by chance alone), and the percentage interpretations  
212 are as follows: 0 % -40% indicates potentially unimportant heterogeneity, 30% -60%  
213 indicates moderate heterogeneity, 50% -90% indicates substantial heterogeneity, and  
214 75% -100% indicates considerable heterogeneity. To explore heterogeneity across  
215 studies, subgroup analysis will be performed using a mixed effects model according to  
216 the following variables: age, ethnicity, sex, and occupational characteristics.

217

## 218 **Patient and public involvement**

219 As this is a systematic review protocol, no patient or public will be involved.  
220

## 221 **Ethics and disclosure**

222 Due to the characteristics of the design of this study, approval by the ethics  
223 committee was not necessary. The results of this systematic review will be disseminated  
224 through peer-reviewed publications, as well as through different media such as symposia  
225 and conferences related to this field. In addition, any changes to this protocol will be  
226 documented with reference to saved searches and analysis methods, which will be  
227 recorded in bibliographic databases for data collection and synthesis.

228

229

## 230 **Discussion**

231 In this systematic review protocol, we clearly describe the study designs,  
232 participants, interventions, and outcomes that will be considered according to the research  
233 question and data sources, search strategy, data extraction, methodological quality of  
234 studies, and synthesis approach. of data. Furthermore, with this protocol study, we  
235 reinforced the clarity of the search strategy and minimized the risk of bias. These results  
236 will provide evidence to inform and personalize shared decision making for healthcare  
237 providers, stakeholders, businesses and government.

238 Therefore, this systematic review will provide relevant evidence on the effects of  
239 long-term COVID among workers and its impact on health status and working life.  
240 Ultimately, we will point to evidence in order to provide subsidies for the development

241 of actions to monitor and care for the health of workers and to guide important strategies  
242 and decision-makers of health policies in several countries.

243 To ensure wider dissemination, we will present the interim findings at local and  
244 international conferences and publish them in high-impact open access journals.

245

246

## 247 **References**

- 248 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. China Novel Coronavirus  
249 Investigating and Research Team. A Novel Coronavirus from Patients with  
250 Pneumonia in China, 2019. *N Engl J Med.* 2020; 382(8): 727-733. doi:  
251 10.1056/NEJMoa2001017.
- 252 2. WHO. WHO Director-General's statement on IHR Emergency Committee on Novel  
253 Coronavirus (2019-nCoV). 2020. Available from: [https://www.who.int/director-](https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-ih-emergency-committee-on-novel-coronavirus-(2019-ncov))  
254 [general/speeches/detail/who-director-general-s-statement-on-ih-emergency-](https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-ih-emergency-committee-on-novel-coronavirus-(2019-ncov))  
255 [committee-on-novel-coronavirus-\(2019-ncov\)](https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-ih-emergency-committee-on-novel-coronavirus-(2019-ncov))
- 256 3. WHO. WHO Director-General's opening remarks at the media briefing on COVID-  
257 19. 11 March 2020. Available from: [https://www.who.int/director-](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)  
258 [general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)  
259 [briefing-on-covid-19---11-march-2020](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
- 260 4. Tang D, Comish P, Kang R. The hallmarks of COVID-19 disease. *PLoS Pathog.*  
261 2020; 16(5): e1008536. doi.: 10.1371/journal.ppat.1008536
- 262 5. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global  
263 health concern. *Lancet.* 2020; 395(10223): 470-473. doi: 10.1016/S0140-  
264 6736(20)30185-9.
- 265 6. WHO. Weekly epidemiological update on COVID-19 - 28 December 2021.  
266 Available from: [https://www.who.int/publications/m/item/weekly-epidemiological-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---28-december-2021)  
267 [update-on-covid-19---28-december-2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---28-december-2021)
- 268 7. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented  
269 infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2).  
270 *Science.* 2020; 368(6490): 489-493. doi: 10.1126/science.abb3221.
- 271 8. Mesquita RR, Silva-Junior LCF, Santana FMS, Oliveira TF, Alcântara RC, Arnozo  
272 GM, et al. Clinical manifestations of COVID-19 in the general population:  
273 systematic review. *Wien Klin Wochenschr.* 2021; 133(7-8): 377-382. doi:  
274 10.1007/s00508-020-01760-4.
- 275 9. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the  
276 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of  
277 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA.*  
278 2020; 323(13): 1239-1242. doi: 10.1001/jama.2020.2648.
- 279 10. Rathore FA, Ilyas A. Post-Intensive Care Syndrome and COVID-19: Crisis After a  
280 Crisis? *Heart Lung Circ.* 2020; 29(12): 1893-1894. doi: 10.1016/j.hlc.2020.08.011.
- 281 11. OPAS. Expandir nosso entendimento da síndrome pós-COVID-19. Relatório de um  
282 webinar da OMS. 9 de fevereiro de 2021. Brasília, D.F.: Organização Pan-  
283 Americana da Saúde; 2021. doi: 10.37774/9789275723999.
- 284 12. CDC. Centers for Diseases Control and Prevention Post-COVID Conditions. 2021.  
285 Available from: <https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/>.
- 286 13. Iqbal A, Iqbal K, Arshad Ali S, Azim D, Farid E, Baig MD, Bin Arif T, Raza M.  
287 The COVID-19 Sequelae: A Cross-Sectional Evaluation of Post-recovery Symptoms



- 288 and the Need for Rehabilitation of COVID-19 Survivors. *Cureus*. 2021; 13(2):  
289 e13080. doi: 10.7759/cureus.13080.
- 290 14. Delbressine JM, Machado FVC, Goërtz YMJ, Van Herck M, Meys R, Houben-  
291 Wilke S, et al. The Impact of Post-COVID-19 Syndrome on Self-Reported Physical  
292 Activity. *Int J Environ Res Public Health*. 2021; 18(11): 6017. doi:  
293 10.3390/ijerph18116017.
- 294 15. Aguiar BF, Sarquis LMM, Miranda FMD. Sequelae of Covid-19: a reflection on the  
295 impacts on the health of the worker. *RSD*. 2021; 10(14):e40101421886. doi:  
296 10.33448/rsd-v10i14.21886.
- 297 16. Martinez MC, Latorre MRDO, Fischer FM. Work ability: a literature review. *Fonte:*  
298 *Ciênc. saúde coletiva*. 2010; 15(supl.1):1553-1561. doi: 10.1590/S1413-  
299 81232010000700067
- 300 17. Rezende ACC, Drumond AS, Fuzikawa AK, Lopes AL, Bracarense ACFL, Oliveira  
301 ACD, compilers. *Guia para Manejo pós-COVID-19 [bibliography on the Internet]*.  
302 Belo Horizonte: [publisher unknown]; 2021 [cited 2022 Feb 17]. Available from:  
303 [https://prefeitura.pbh.gov.br/sites/default/files/estrutura-de-](https://prefeitura.pbh.gov.br/sites/default/files/estrutura-de-governo/saude/2021/guia_manejo_pos-covid-21-09-2021.pdf)  
304 [governo/saude/2021/guia\\_manejo\\_pos-covid-21-09-2021.pdf](https://prefeitura.pbh.gov.br/sites/default/files/estrutura-de-governo/saude/2021/guia_manejo_pos-covid-21-09-2021.pdf).
- 305 18. Madan I, Briggs TA, Chew-Graham C, Cullinan P, Henderson M, Man W, et al.  
306 Guidance for healthcare professionals on return to work for patients with long-  
307 COVID. Faculty of Occupational Medicine of the Royal of Physicians, 2021.  
308 Available from: [https://www.fom.ac.uk/wp-](https://www.fom.ac.uk/wp-content/uploads/longCOVID_guidance_04.pdf)  
309 [content/uploads/longCOVID\\_guidance\\_04.pdf](https://www.fom.ac.uk/wp-content/uploads/longCOVID_guidance_04.pdf).
- 310 19. Morgan RL, Whaley P, Thayer KA, Schünemann HJ. Identifying the PECO: A  
311 framework for formulating good questions to explore the association of  
312 environmental and other exposures with health outcomes. *Environ Int*. 2018; 121(Pt.  
313 1): 1027-1031. doi: 10.1016/j.envint.2018.07.015.
- 314 20. Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf M-I, et al.  
315 Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler  
316 J, Cumpston M, Li T, Page MJ, et al. (editors). *Cochrane Handbook for Systematic*  
317 *Reviews of Interventions version 6.2*. Cochrane, 2021. Available from:  
318 [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
- 319 21. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.  
320 The PRISMA 2020 statement: an updated guideline for reporting systematic  
321 reviews. *BMJ*. 2021; 372 (71). doi: 10.1136/bmj.n71.
- 322 22. Ouzzani M, Hammady H, Fedorowicz Z. Rayyan—a web and mobile app for  
323 systematic reviews. *Syst Rev*. 2016; 5(210). doi: 10.1186/s13643-016-0384-4.
- 324 23. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological  
325 index for non-randomized studies (minors): development and validation of a new  
326 instrument. *ANZ J Surg*. 2003; 73(9), 712–716. doi: 10.1046/j.1445-  
327 2197.2003.02748.x.